French independent pharma major Servier is ramping up its industrial development with the inauguration of a new production unit for the active ingredient of one of its venous medicines. Venous ...

Black Diamond Therapeutics' strategic deal with Servier makes BDTX undervalued, with a $70M upfront payment and potential $710M in milestone payments and royalties. BDTX is trading below its net ...

The new semi-transparent solar cell was developed by a scientific team comprising nine partners from seven countries and was funded by the EU-backed CitySolar project.

The therapy is undergoing Phase I clinical development. Credit: Alex_Traksel/Shutterstock. Servier and Black Diamond Therapeutics have signed a licensing agreement ...

The partnership underscores Servier's commitment to developing targeted therapies that address unmet medical needs in oncology Servier will develop and commercialize BDTX-4933, a Phase 1 asset ...

Black Di­a­mond Ther­a­peu­tics has found a buy­er for an ear­ly-stage tar­get­ed can­cer drug, which was brushed to the side last year as it fo­cused re­sources … ...

Servier will lead the development activities and the worldwide commercialization of BDTX-4933 across multiple indications. Currently, in Phase 1 development, BDTX-4933 is designed to target RAS ...

Five months after cutting support for BDTX-4933, the biotech has licensed the RAF inhibitor to Servier for $70 million upfront and up to $710 million in milestones. In October, Black Diamond ...

SURESNES, France and CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group governed by a non-profit foundation, and Black Diamond Therapeutics ...

Black Diamond has got itself a longer runway, securing a licensing deal with French pharmaceutical group Servier for an early-stage small molecule cancer drug Black Diamond backburnered last year. The ...